Journal
TROPICAL MEDICINE & INTERNATIONAL HEALTH
Volume 16, Issue 1, Pages 79-83Publisher
WILEY
DOI: 10.1111/j.1365-3156.2010.02665.x
Keywords
Mycobacterium tuberculosis; tuberculosis; latency; isoniazid; immunology; preventive therapy; re-activation; MDR; XDR-TB; Mycobacterium tuberculosis; tuberculose; latence; isoniazide; immunologie; traitement preventif; reactivation; TB MDR; UR; Mycobacterium tuberculosis; tuberculosis; latencia; isoniazida; inmunologia; terapia preventiva; reactivacion; tuberculosis multirresistente y extremadamente resistente (MDR; XDR-TB)
Ask authors/readers for more resources
Worldwide, there are nearly 10 million new cases of active TB and 1.8 million associated deaths every year. WHO estimates that one-third of the world's population is infected with Mycobacterium tuberculosis (Mtb), forming a huge latent Mtb global reservoir. This renders the prospect of ever eliminating Mtb from the human race almost impossible. Several controversial issues regarding host-pathogen interactions and existing prevention and eradication strategies for latent Mtb infections need to be critically re-examined. In this viewpoint, widely held assumptions on Mtb latency and isoniazid monotherapy and chemoprophylaxis are challenged. We highlight the need for future research to resolve these issues and to develop evidence-based strategies for better understanding of equilibrium and escape of Mtb in the human body, eventually leading to global recommendations for elimination of the latent Mtb state through informed policy and practice. Until such strategies and policies are realized, WHO and TB experts will have to settle for global TB control rather than eradication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available